JP2022506761A5 - - Google Patents
Info
- Publication number
- JP2022506761A5 JP2022506761A5 JP2021524345A JP2021524345A JP2022506761A5 JP 2022506761 A5 JP2022506761 A5 JP 2022506761A5 JP 2021524345 A JP2021524345 A JP 2021524345A JP 2021524345 A JP2021524345 A JP 2021524345A JP 2022506761 A5 JP2022506761 A5 JP 2022506761A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144789A JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203183.1 | 2018-10-29 | ||
| EP18203183 | 2018-10-29 | ||
| US201862752641P | 2018-10-30 | 2018-10-30 | |
| US62/752,641 | 2018-10-30 | ||
| PCT/US2019/058648 WO2020092427A1 (en) | 2018-10-29 | 2019-10-29 | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144789A Division JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506761A JP2022506761A (ja) | 2022-01-17 |
| JPWO2020092427A5 JPWO2020092427A5 (https=) | 2022-10-31 |
| JP2022506761A5 true JP2022506761A5 (https=) | 2022-10-31 |
Family
ID=70462698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Pending JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
| JP2024144789A Pending JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144789A Pending JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210332131A1 (https=) |
| EP (1) | EP3873942A4 (https=) |
| JP (2) | JP2022506761A (https=) |
| KR (1) | KR20210096612A (https=) |
| CN (1) | CN113260632A (https=) |
| AU (1) | AU2019369397A1 (https=) |
| CA (1) | CA3118312A1 (https=) |
| GB (1) | GB2596411B (https=) |
| WO (1) | WO2020092427A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220004979A (ko) * | 2019-03-27 | 2022-01-12 | 유엠씨 우트레크트 홀딩 비.브이. | 조작된 iga 항체 및 사용 방법 |
| CA3196402A1 (en) * | 2020-10-22 | 2022-04-28 | Dale L. Ludwig | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| WO2022125439A2 (en) * | 2020-12-07 | 2022-06-16 | The Regents Of The University Of California | Innate immune cell silencing by sirp-alpha engager |
| CN116731161A (zh) * | 2021-09-18 | 2023-09-12 | 南开大学 | 工程化IgG和IgA嵌合的“四叶草型X抗体” |
| WO2023154730A2 (en) * | 2022-02-09 | 2023-08-17 | Exelixis, Inc. | Multispecific binding agents and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226878D0 (en) * | 2002-11-18 | 2002-12-24 | Univ Warwick | Antibodies |
| ES2672640T3 (es) * | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| HRP20170374T1 (hr) * | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biološki proizvodi |
| EP2477648B1 (en) * | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| WO2013087912A1 (en) * | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| CN105121467B (zh) * | 2012-12-03 | 2019-07-05 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
| US20140213771A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Multi-specific binding proteins |
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| BR112016015140A2 (pt) * | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| US10087257B2 (en) * | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
| HUE046661T2 (hu) * | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
| NZ741324A (en) * | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| HUE073389T2 (hu) * | 2016-09-01 | 2026-01-28 | Tigatx Inc | CD20 antitestek |
| EP3574009A4 (en) * | 2017-01-26 | 2020-11-25 | Zlip Holding Limited | CD47 ANTIGEN BINDING UNIT AND ITS USES |
| AU2018308191B2 (en) * | 2017-07-24 | 2023-12-21 | Scenic Immunology B.V. | Treating pathological conditions by direct and indirect targeting of SIRPa - CD47 interaction |
| ES2933256T3 (es) * | 2017-08-08 | 2023-02-03 | Hoffmann La Roche | Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG |
-
2019
- 2019-10-29 KR KR1020217016137A patent/KR20210096612A/ko not_active Ceased
- 2019-10-29 GB GB2107478.6A patent/GB2596411B/en active Active
- 2019-10-29 WO PCT/US2019/058648 patent/WO2020092427A1/en not_active Ceased
- 2019-10-29 CN CN201980087109.4A patent/CN113260632A/zh active Pending
- 2019-10-29 JP JP2021524345A patent/JP2022506761A/ja active Pending
- 2019-10-29 EP EP19879444.8A patent/EP3873942A4/en active Pending
- 2019-10-29 AU AU2019369397A patent/AU2019369397A1/en active Pending
- 2019-10-29 CA CA3118312A patent/CA3118312A1/en active Pending
-
2021
- 2021-04-28 US US17/242,793 patent/US20210332131A1/en active Pending
-
2024
- 2024-08-26 JP JP2024144789A patent/JP2024170456A/ja active Pending